FOR 2240: (Lymph)Angiogenesis And Cellular Immunity In Inflammatory Diseases Of The Eye

眼睛致盲性疾病通常与年龄有关，通常伴有与病理性（淋巴）血管生成相关的异常炎症过程。这个研究单位的目的是1。为了更好地了解眼睛炎症性疾病的发病机制和2。在此基础上，通过靶向异常（淋巴）血管生成和细胞免疫间接调节炎症过程，开发新的治疗理念来预防失明。2240年研究股更新的总体目标是：为延长第一期（2015-2018年）成功实施的项目，2 .及时增加两个新项目，对2240年会的总体主题有新的认识（“角膜缘干细胞在角膜淋巴血管生成特权中的作用”和“淋巴和血管生成接种移植物抗宿主病”）。增加年轻和女性科学家以及相关领域（OCTimaging， uv诱导DNA损伤，GvHD）的知名专家到pi / coapplicantgroup和4。进一步加强for2240项目之间已经在进行的协同合作。在主题上，补充第一个资助期的开放性问题，我们的概念是更好地了解各种视力威胁，免疫介导，炎症和年龄相关的眼部疾病的发病机制，包括年龄相关性黄斑变性（AMD），干眼病，角膜移植排斥反应，葡萄膜炎和眼部肿瘤，特别关注病理性眼（淋巴）血管生成和细胞免疫失调的机制作用。我们取得的进展的一个标志是，在第一个资助期内，FOR pi已经提交了4项专利申请，这也表明了我们对翻译相关研究的承诺。我们希望在我们成功的基础上继续努力，在更好地理解这些疾病的关键免疫和血管事件的基础上，在开发新的治疗概念方面取得与翻译相关的进展。

Blinding diseases of the eye are often age-related and usuallyaccompanied by aberrant inflammatory processes which areassociated with pathological (lymph)angiogenesis. The aim of thisResearch Unit is 1. to better understand the pathogenesis ofinflammatory diseases of the eye and 2. based on that, to developnovel therapeutic concepts to prevent blindness based on indirectmodulation of inflammatory processes via targeting aberrant(lymph)angiogenesis and cellular imunity. The overall objectives ofthis renewal of Research Unit FOR 2240 are: 1. to extend thesuccessfully running projects of the first funding period (2015-2018),2. to add two new projects with timely new aspects of the overalltheme of the FOR 2240 (“role of limbal stem cells in corneallymphangiogenic privilege” and “lymph- and hemangiogenesis inocular graft-versus-host disease”), 3. to add young and femalescientists as well as established experts from associated areas (OCTimaging, UV-induced DNA damage, GvHD) to the group of PIs/Coapplicantsand 4. to further intensify the already ongoing synergisticcooperations between the FOR 2240 projects. Thematically,complementing the open questions from the first funding period, ourconcept is to better understand the pathogenesis of a diverse group ofsight-threatening, immune-mediated, inflammatory and age-relatedeye diseases, including age-related macular degeneration (AMD), dryeye disease, corneal graft rejection, uveitis and ocular tumors, with aspecial focus on the mechanistic role of pathologic ocular(lymph)angiogenesis and dysregulated cellular immunity. One sign ofour progress that also demonstrates the commitment we have madeto do translationally relevant research are the 4 patent applicationsthat have been filed in the first funding period by FOR PIs. We want tobuild on our successes and continue our efforts to maketranslationally relevant progress in developing new therapeuticconcepts based on a better understanding of key immunological andvascular events in these diseases.